Tadahiko Shien

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 17

Top Topics

Estrogen Receptor

Top Venues

Scientific reports

Japanese journal of clinical oncology

Pathology international

This page only lists publications with an associated author ORCID identifier.

Publications

Shogo Nakamoto, Tadahiko Shien, Takayuki Iwamoto, Shinichiro Kubo, Mari Yamamoto, Tetsumasa Yamashita, Chihiro Kuwahara, Masahiko Ikeda
Absolute lymphocyte count and neutrophil-to-lymphocyte ratio as predictors of CDK 4/6 inhibitor efficacy in advanced breast cancer. Scientific reports 14 (1) (2024)
Hnin-Wint-Wint Swe, Masayoshi Fujisawa, Toshiaki Ohara, Yu Komatsubara, Teizo Yoshimura, Tadahiko Shien, Akihiro Matsukawa
The specific shapes of capillaries are associated with worse prognosis in patients with invasive breast cancer. Pathology international 74 (7) (2024)
Yusuke Otani, Haruyoshi Katayama, Yidan Zhu, Rongsheng Huang, Takafumi Shigehira, Kazuhiko Shien, Ken Suzawa, Hiromasa Yamamoto, Tadahiko Shien, Shinichi Toyooka, Atsushi Fujimura
Adrenergic microenvironment driven by cancer-associated Schwann cells contributes to chemoresistance in patients with lung cancer. Cancer science (2024)
Yusuke Otani, Haruyoshi Katayama, Yidan Zhu, Rongsheng Huang, Takafumi Shigehira, Kazuhiko Shien, Ken Suzawa, Hiromasa Yamamoto, Tadahiko Shien, Shinichi Toyooka, Atsushi Fujimura
Adrenergic microenvironment driven by cancer-associated Schwann cells contributes to chemoresistance in patients with lung cancer. Cancer science 115 (7) (2024)
Shogo Nakamoto, Tadahiko Shien, Takayuki Iwamoto, Shinichiro Kubo, Mari Yamamoto, Tetsumasa Yamashita, Chihiro Kuwahara, Masahiko Ikeda
Absolute lymphocyte count and neutrophil-to-lymphocyte ratio as predictors of CDK 4/6 inhibitor efficacy in advanced breast cancer. Scientific reports 14 (1) (2024)
Yusuke Otani, Haruyoshi Katayama, Yidan Zhu, Rongsheng Huang, Takafumi Shigehira, Kazuhiko Shien, Ken Suzawa, Hiromasa Yamamoto, Tadahiko Shien, Shinichi Toyooka, Atsushi Fujimura
Adrenergic microenvironment driven by cancer-associated Schwann cells contributes to chemoresistance in patients with lung cancer. Cancer science 115 (7) (2024)
Hnin-Wint-Wint Swe, Masayoshi Fujisawa, Toshiaki Ohara, Yu Komatsubara, Teizo Yoshimura, Tadahiko Shien, Akihiro Matsukawa
The specific shapes of capillaries are associated with worse prognosis in patients with invasive breast cancer. Pathology international (2024)
Yusuke Otani, Haruyoshi Katayama, Yidan Zhu, Rongsheng Huang, Takafumi Shigehira, Kazuhiko Shien, Ken Suzawa, Hiromasa Yamamoto, Tadahiko Shien, Shinichi Toyooka, Atsushi Fujimura
Adrenergic microenvironment driven by cancer-associated Schwann cells contributes to chemoresistance in patients with lung cancer. Cancer science 115 (7) (2024)
Yusuke Otani, Haruyoshi Katayama, Yidan Zhu, Rongsheng Huang, Takafumi Shigehira, Kazuhiko Shien, Ken Suzawa, Hiromasa Yamamoto, Tadahiko Shien, Shinichi Toyooka, Atsushi Fujimura
Adrenergic microenvironment driven by cancer-associated Schwann cells contributes to chemoresistance in patients with lung cancer. Cancer science 115 (7) (2024)
Tsuguo Iwatani, Keita Sasaki, Ryunosuke Machida, Tadahiko Shien, Fumikata Hara, Tomomi Fujisawa, Yuko Takano, Yoshie Kobayashi, Michiyo Saimura, Kei Koizumi, Mitsuo Terada, Shinsuke Sasada, Kanako Saito, Miwa Sumiyoshi, Hiroji Iwata
Status of incremental costs of first-line treatment recommended in Japanese clinical guidelines for metastatic breast cancer patients. Japanese journal of clinical oncology (2024)
Shinsuke Sasada, Naoto Kondo, Hiroya Hashimoto, Yuko Takahashi, Kaori Terata, Kumiko Kida, Yasuaki Sagara, Takayuki Ueno, Keisei Anan, Akihiko Suto, Chizuko Kanbayashi, Mina Takahashi, Rikiya Nakamura, Toshiyuki Ishiba, Michiko Tsuneizumi, Seiichiro Nishimura, Yoichi Naito, Fumikata Hara, Tadahiko Shien, Hiroji Iwata
Prognostic impact of adjuvant endocrine therapy for estrogen receptor-positive and HER2-negative T1a/bN0M0 breast cancer. Breast cancer research and treatment (2023)
Toshiyuki Ishiba, Ikuno Nishibuchi, Fumikata Hara, Naoto Shikama, Tadahiko Shien, Hiroji Iwata
Metastasis-directed therapy for oligometastases in breast cancer. Japanese journal of clinical oncology (2023)
Kosuke Ochi, Ken Suzawa, Yin Min Thu, Fumiaki Takatsu, Shimpei Tsudaka, Yidan Zhu, Kentaro Nakata, Tatsuaki Takeda, Kazuhiko Shien, Hiromasa Yamamoto, Mikio Okazaki, Seiichiro Sugimoto, Tadahiko Shien, Yoshiharu Okamoto, Shuta Tomida, Shinichi Toyooka
Drug repositioning of tranilast to sensitize a cancer therapy by targeting cancer-associated fibroblast. Cancer science 113 (10) (2022)
Miwa Fujihara, Tadahiko Shien, Kazuhiko Shien, Ken Suzawa, Tatsuaki Takeda, Yidan Zhu, Tomoka Mamori, Yusuke Otani, Ryo Yoshioka, Maya Uno, Yoko Suzuki, Yuko Abe, Minami Hatono, Takahiro Tsukioki, Yuko Takahashi, Mariko Kochi, Takayuki Iwamoto, Naruto Taira, Hiroyoshi Doihara, Shinichi Toyooka
YES1 as a Therapeutic Target for HER2-Positive Breast Cancer after Trastuzumab and Trastuzumab-Emtansine (T-DM1) Resistance Development. International journal of molecular sciences 22 (23) (2021)
Takahiro Tsukioki, Tadahiko Shien, Takehiro Tanaka, Yoko Suzuki, Yukiko Kajihara, Minami Hatono, Kengo Kawada, Mariko Kochi, Takayuki Iwamoto, Hirokuni Ikeda, Naruto Taira, Hiroyoshi Doihara, Shinichi Toyooka
Influences of preoperative metformin on immunological factors in early breast cancer. Cancer chemotherapy and pharmacology 86 (1) (2020)
Takayuki Iwamoto, Naoki Niikura, Rin Ogiya, Hiroyuki Yasojima, Ken-Ichi Watanabe, Chizuko Kanbayashi, Michiko Tsuneizumi, Akira Matsui, Tomomi Fujisawa, Tsutomu Iwasa, Tadahiko Shien, Shigehira Saji, Norikazu Masuda, Hiroji Iwata
Distinct gene expression profiles between primary breast cancers and brain metastases from pair-matched samples. Scientific reports 9 (1) (2019)
Tadahiko Shien, Hiroyoshi Doihara, Nobuaki Sato, Keisei Anan, Kansei Komaki, Keisuke Miyauchi, Yasuhiro Yanagita, Tomomi Fujisawa, Shoshu Mitsuyama, Chizuko Kanbayashi, Mikihiro Kusama, Morihiko Kimura, Hiromitsu Jinno, Muneaki Sano, Tadashi Ikeda
Serum lipid and bone metabolism effects of Toremifene vs. Letrozole as adjuvant therapy for postmenopausal early breast cancer patients: results of a multicenter open randomized study. Cancer chemotherapy and pharmacology 81 (2) (2017)